Clarius Group LLC’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $3.83M | Sell |
16,746
-1,226
| -7% | -$279K | 0.22% | 49 |
|
|
2025
Q3 | $4.16M | Sell |
17,972
-3,687
| -17% | -$751K | 0.25% | 47 |
|
|
2025
Q2 | $4.02M | Buy |
21,659
+1,511
| +7% | +$281K | 0.23% | 49 |
|
|
2025
Q1 | $4.22M | Buy |
20,148
+4,218
| +26% | +$820K | 0.27% | 47 |
|
|
2024
Q4 | $2.83M | Sell |
15,930
-321
| -2% | -$59K | 0.19% | 55 |
|
|
2024
Q3 | $3.2M | Sell |
16,251
-435
| -3% | -$81.2K | 0.22% | 51 |
|
|
2024
Q2 | $2.86M | Sell |
16,686
-472
| -3% | -$78.2K | 0.2% | 52 |
|
|
2024
Q1 | $3.12M | Sell |
17,158
-1,769
| -9% | -$305K | 0.22% | 51 |
|
|
2023
Q4 | $2.93M | Buy |
18,927
+3,381
| +22% | +$493K | 0.24% | 55 |
|
|
2023
Q3 | $2.32M | Sell |
15,546
-4,439
| -22% | -$652K | 0.22% | 57 |
|
|
2023
Q2 | $2.69M | Buy |
19,985
+206
| +1% | +$30.2K | 0.21% | 58 |
|
|
2023
Q1 | $3.15M | Buy |
19,779
+608
| +3% | +$93K | 0.27% | 47 |
|
|
2022
Q4 | $3.1M | Buy |
19,171
+238
| +1% | +$36.5K | 0.28% | 52 |
|
|
2022
Q3 | $2.54M | Buy |
18,933
+463
| +3% | +$66.4K | 0.25% | 54 |
|
|
2022
Q2 | $2.83M | Buy |
18,470
+573
| +3% | +$87.6K | 0.28% | 48 |
|
|
2022
Q1 | $2.42M | Hold |
17,897
| – | – | 0.19% | 61 |
|
|
2021
Q4 | $2.42M | Buy |
17,897
+395
| +2% | +$46.7K | 0.19% | 61 |
|
|
2021
Q3 | $1.89M | Buy |
17,502
+418
| +2% | +$47.8K | 0.17% | 71 |
|
|
2021
Q2 | $1.92M | Buy |
17,084
+202
| +1% | +$22.8K | 0.17% | 68 |
|
|
2021
Q1 | $1.83M | Buy |
16,882
+1,789
| +12% | +$191K | 0.18% | 62 |
|
|
2020
Q4 | $1.62M | Buy |
15,093
+1,342
| +10% | +$129K | 0.17% | 66 |
|
|
2020
Q3 | $1.2M | Sell |
13,751
-128
| -0.9% | -$12.1K | 0.15% | 72 |
|
|
2020
Q2 | $1.36M | Buy |
13,879
+3,824
| +38% | +$337K | 0.19% | 63 |
|
|
2020
Q1 | $766K | Buy |
10,055
+296
| +3% | +$25.2K | 0.14% | 85 |
|
|
2019
Q4 | $871K | Buy |
9,759
+801
| +9% | +$66.5K | 0.14% | 86 |
|
|
2019
Q3 | $678K | Sell |
8,958
-777
| -8% | -$53.3K | 0.12% | 96 |
|
|
2019
Q2 | $708K | Buy |
9,735
+4,948
| +103% | +$389K | 0.14% | 83 |
|
|
2019
Q1 | $386K | Buy |
4,787
+863
| +22% | +$70.6K | 0.09% | 115 |
|
|
2018
Q4 | $362K | Buy |
3,924
+998
| +34% | +$87.8K | 0.13% | 80 |
|
|
2018
Q3 | $277K | Buy |
+2,926
| New | +$277K | 0.1% | 93 |
|
|
2017
Q3 | – | Sell |
-2,845
| Closed | -$206K | – | 71 |
|
|
2017
Q2 | $206K | Buy |
+2,845
| New | +$191K | 0.08% | 88 |
|
Other funds holding ABBV
Clarius Group LLC's ABBV Position: Q4 2025 in Review
Clarius Group LLC reduced its AbbVie (ABBV) stake by 6.8% in Q4 2025, selling an estimated $279K and leaving 16,746 shares worth $3.83M. The position accounts for 0.22% of the portfolio, ranked #49.
Clarius Group LLC first reported a position in ABBV in Q2 2017 and has held it in 31 quarters since. The position peaked at $4.22M in Q1 2025. 4,147 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.
- Clarius Group LLC held 16,746 shares of AbbVie worth $3.83M as of Q4 2025.
- Clarius Group LLC sold 1,226 AbbVie shares in Q4 2025, an estimated $279K.
- AbbVie made up 0.22% of Clarius Group LLC's portfolio in Q4 2025, its #49 holding.
- Clarius Group LLC first reported a position in AbbVie in Q2 2017 and has held it in 31 quarters since.
- Clarius Group LLC's AbbVie position peaked at $4.22M in Q1 2025.
- 4,147 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.
Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.